Please assess the completion status of the following clinical trial:

Trial Title: Acute Unilateral Vestibulopathy and Corticosteroid Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* definite unilateral vestibulopathy~* no pathological HINTS (examination criteria in acute vestibular syndrome)~* capable of making their own decisions~Exclusion Criteria:~* tinnitus or hearing loss with same debut as vertigo~* history of bleeding peptic ulcer~* glaucoma~* pregnancy or non-acceptance to use anticonception measures during 13 days after debut~* high blood pressure \>180 systolic, 105, diastolic~* ketoacidosis with a Base Excess \>=2~* psychic disorder (not including mild depression)~* serious infection (neutropenia, tuberculosis)~* chronic otitis~* history of vertiginous disease; Ménière, Vertiginous migraine, atypical BPPV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Day 1: Intravenous sodium-chloride 2ml Day 2-6: 10 tablets placebo Day 7: 8 tablets placebo Day 8: 6 tablets placebo Day 9: 4 tablets placebo Day 10: 2 tablets placebo Day 11: 1 tablet placebo
- Short treatment (Type: ACTIVE_COMPARATOR): Day 1: Intravenous betamethasone 8mg (2ml of 4mg/ml) Day 2-3: 10 tablets prednisolone 5 mg Day 4-6: 10 tablets placebo Day 7: 8 tablets placebo Day 8: 6 tablets placebo Day 9: 4 tablets placebo Day 10: 2 tablets placebo Day 11: 1 tablet placebo
- Standard treatment (Type: ACTIVE_COMPARATOR): Day 1: Intravenous betamethasone 8mg (2ml of 4mg/ml) Day 2-6: 10 tablets prednisolone 5 mg Day 7: 8 tablets prednisolone 5 mg Day 8: 6 tablets prednisolone 5 mg Day 9: 4 tablets prednisolone 5 mg Day 10: 2 tablets prednisolone 5 mg Day 11: 1 tablet prednisolone 5 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).